Showing 251–275 of 278
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $346.8m (+1.4%); operating margin 6.0%; net income $4.4m.
Cash $24.9m; debt $164.6m.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Listed (688271.SS).
Latest full-year results not yet captured by HSH.
Parent Siemens Healthineers (SHL.DE) group FY2026 revenue €23.60bn; adjusted EBIT margin 16.2%.
Comparable revenue growth 4.0%; adjusted EBIT about €3.8bn. Net income not captured.
FY2026 revenue $3.20bn (+16.3%); operating margin 28.7%; net income $908.9m.
No debt; $6.56bn cash and short-term investments.
Listed (MDRX).
Latest full-year results not yet captured by HSH.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Listed (338220.KQ).
Latest full-year results not yet captured by HSH.
FY2025 revenue $1.10bn (+17.0%); operating margin 22.7%; net income $112.1m.
Balance sheet figures not captured from release.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue C$1.40bn (+52.2%); net income C$4.5m.
Revenue +52%; total net income C$4.5m. Attributable result not captured.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Listed (300253.SZ).
Latest full-year results not yet captured by HSH.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Parent Wolters Kluwer (WKL.AS) group FY2025 revenue €6.12bn (+3.5%); operating margin 28.3%; net income €1.31bn.
Health division revenue €1.60bn (+5% organic); net debt €4.02bn.
FY2026 revenue $9.55bn (+13.1%); operating margin 7.5%; net income $693.0m.
Cash $5.44bn; debt $2.99bn.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.